Inclusion Criteria:

- Patients of ALL or NHL. For ALL must have histologic diagnosis with >10% blasts in the marrow
and for lymphoblastic lymphoma or peripheral T-cell lymphoma must have radiologic or
physical evidence of recurrence.

- Lansky > 50% or Karnofsky > 50%

- Negative Pregnancy Test

- Creatinine clearance or radioisotope GFR > 70ml/min/m2 OR serum creatinine based on
age /gender

- Pulse ox >94%

- Total Bilirubin <1.5 x normal for age

- ALT < 5 x normal for age

- Albumin > 2g/dL

- Shortening fraction by echo > 28% OR ejection fraction > 50% by gated radionuclide
study

Exclusion Criteria:

- Patient has known allergies to sirolimus,FK-506 or mTOR inhibitors

- Patient is taking other investigational anti-neoplastic drugs

- Patient received no myelosuppressive chemo within 14 days

- < 14 days have elapsed since local palliative XRT (small port) < 28 days since prior
craniospinal XRT or 50% radiation of pelvis <28 days if other substantial BM
radiation

- Hematopoietic growth factors within 7 days of entry (except erythropoietin.)

- Patient has taken any biologic agents within 14 days

- Post BMT/SCT - evidence of active GVHD, at least > 3 months must have elapsed

- Patient has uncontrolled infection (if patients with fungal disease, stable for < 14
days and patients with bacteremia without negative blood culture

- Existing non-hematologic toxicities > grade 2

Use of steroids or hydroxyurea is permitted upto 14 days prior to entry.